Shoot to Kill: Baltimore ranks as most lethal among nation's largest cities

NASDAQ

Osiris Therapeutics receives deficiency notice from Nasdaq

Osiris Therapeutics receives deficiency notice from Nasdaq

Osiris Therapeutics Inc., the troubled Columbia-based biotechnology firm that saw its CEO resign last month, said Tuesday it has been notified of a failure to comply with rules for listing on the Nasdaq Stock Market.

NASDAQ notified Osiris March 17 that it did not file its annual report for the year ended Dec. 31 on a timely basis with the U.S. Securities and Exchange Commission. To continue to be listed, the company must submit a plan to regain compliance within 60 days.

The company previously disclosed that it is completing an accounting review of revenue under contracts with distributors, amending some prior earnings reports filed with SEC and moving to a new independent...

64°